STUDIO
Prolevi Bio on the financing round and focus for 2023
Privately held Prolevi Bio aims improve treatment for many patients suffering from hypoterosis. The company has developed a method that is to improve the drug...
RECOMMENDED READING
Annexin’s CEO: “The cancer area more than doubles the potential”
Annexin Pharmaceuticals' candidate ANXV is being developed as a new treatment for retinal vein...
LS cluster in Gothenburg: a successful experiment
Life Science is an important sector for western Sweden's business community, and the life...